Marion Surgical

Marion Surgical

We're innovating with VR/AR to create realistic simulations for surgeons, enhancing skills in a safe, virtual environment. Celebrating our AFWERX Phase 1 contract win, we have exclusive rights to bring patented medtech to the Department of Defense.

Print
Claim My Business
Security Type
Common Stock
Min Investment
$100
Offering Date
September 25, 2024
Expected Close Date
December 07, 2024
Target Raise
$1.00M
Security Price
$20
Valuation
$2,006,100

Company Description

Welcome to Marion Surgical, where we're transforming the way surgeons train for complex procedures. Our focus is on harnessing the power of virtual and augmented reality with haptics (touch) to create a realistic, interactive training environment for minimally invasive and robotic surgery. This approach not only enhances the learning experience but also improves patient outcomes by sharpening surgeons' skills. Our team, comprised of experts in medical technology, software development, and education, has already made significant strides. We've secured a Phase 1 AFWERX contract, an acknowledgment of our potential to make a substantial impact in surgical training. Additionally, we hold exclusive rights to a sell and further develop a patented technology to the DOD. Our vision is to become a key player in the field of medical education, providing tools that enable surgeons around the world to practice and perfect their craft without risk.We're not just creating products; we're building a new standard in surgical training.We invite you to join us on this journey. Together, we can contribute to the advancement of medical education and ultimately, improve the quality of healthcare globally. 5% of our fundraise is planned to go to sending a simulator as part of a training mission initiative in Savanna La Mar Jamaica. According to the Lancet Commission on Global Surgery, up to 5 billion people around the world do not have access to adequate surgical care. The Lancet Commission report in 2015 estimated that more people die as a result of inadequate access to surgical care than malaria, TB and HIV combined.

Management Team / Advisory Board Bios

Ben Sainsbury

CEO

A unique blend of technical innovation and entrepreneurial expertise to the table, grounded in his development of our core patented technology during his PhD in Computer Science. He has a strong track record in launching start-ups, securing equity and debt financing, and leading high-performance teams, which are crucial for our venture's growth. With a focus on creating shareholder value, Ben's experience and leadership make him and our team exceptionally suited to realize the potential of this venture, offering both financial returns and a commitment to innovation and excellence.




Dr. Rajiv Singal

Head of Medical Technology
Dr. Singal currently is the Surgeon in Chief at Michael Garron Hospital. He also leads the Surgical Robotics Program jointly run by Michael Garron Hospital and Sunnybrook Health Sciences Centre. He was Head, Division of Urology, Department of Surgery at the Michael Garron Hospital from July 2001 until October 2012 and is an Associate Professor within the Department of Surgery at the University of Toronto. He supervises the Clinical Endourology Fellowship program at MGH under the umbrella of the University of Toronto and also teaches undergraduate and postgraduate medical trainees.





Tim Averch

Medical Advisor

Timothy D. Averch, M.D., F.A.C.S., Professor and Vice Chair for Quality, Director of Endourology, UPMC Department of Urology; Chair, AUA Quality Improvement and Patient Safety Committee Dr. Averch graduated from the University of Pittsburgh School of Medicine and went on to complete his Urology training at New York Medical College. Following his residency, he completed a fellowship in Endourology at Johns Hopkins Hospitals. Dr. Averch is currently Vice Chair for Quality and Professor of Urology at the University of Pittsburgh Medical Center and is the Director of Endourology. He is currently Chair for the AUA Quality Improvement and Patient Safety committee. He is certified by the American Board of Urology.




Dr. Mitch Goldenberg

Medical Advisor

Dr. Goldenberg is an Assistant Professor of Clinical Urology at the Keck School of Medicine of USC. He obtained his medical degree at St. George’s, University of London in London, England before completing his urology residency at the University of Toronto in Toronto, Canada. During residency, he participated in the Surgeon Scientist Training Program, completing a PhD in Surgical Education. His research focuses on the assessment of surgical skills and studying the role of artificial intelligence as a tool in medical education and patient safety.
Amount Raised : $260
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments